TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Silexion Therapeutics Corp.
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer

Silexion Therapeutics received formal written Scientific Advice from the German Federal Institute for Drugs and Medical Devices regarding its planned Phase 2/3 clinical trial for SIL204, a potential treatment for locally advanced pancreatic cancer. The guidance provides regulatory clarity and supports the company's planned trial initiation in Q2 2026.

Insights
AMZN   neutral

Mentioned as a potential investment target, but no strong positive or negative signals in the article


SLXN   positive

Received positive regulatory feedback, on track with clinical trial plans, advancing product development for pancreatic cancer treatment